Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study - DTU Orbit (01/05/2019)

Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study: Design and early dosimetric results of a randomized, multi-centre phase-III study


Research output: Contribution to journal › Journal article – Annual report year: 2017 › Research › peer-review